

Plasma Antioxidants and Asymptomatic Carotid Atherosclerotic Disease

Graziano Riccioni^a Tonino Bucciarelli^c Nicolantonio D'Orazio^d
Nicola Palumbo^b Emanuela di Ilio^c Francesco Corradi^c Alfonso Pennelli^c
Lydia A. Bazzano^e

^aCardiology Unit and ^bAnalysis Laboratory, 'San Camillo de Lellis' Hospital, Manfredonia, and
^cClinical Biochemistry Laboratory and ^dHuman Nutrition, Department of Biomedical Science,
University 'G. D'Annunzio', Chieti, Italy; ^eDepartment of Epidemiology, Tulane University School of
Public Health and Tropical Medicine, New Orleans, La., USA

Key Words

Atherosclerosis • Carotid arteries • Antioxidants • Lycopene • Vitamin A • Vitamin E • β -Carotene

Abstract

Background: Atherosclerosis remains clinically mute for a long time and frequently manifests itself with an acute cardiovascular event. The possibility of detecting this disease in a subclinical phase and reducing or reversing its progression is an issue of relevance. Published studies on the association between antioxidant vitamins and carotenoids and carotid intima-media thickness (CIMT) have been inconclusive. **Methods:** We enrolled 220 consecutive, asymptomatic participants. After carotid ultrasound investigation, a medical history was taken, a physical examination was performed and venous blood samples were collected. Venous blood samples were analyzed for concentrations of antioxidant vitamins and carotenoids. **Results:** Low concentrations of vitamin A ($p < 0.01$), vitamin E ($p < 0.001$), lycopene ($p < 0.01$) and β -carotene ($p < 0.001$) were significantly associated with carotid atherosclerosis (CIMT ≥ 0.8 mm). In addition, marginally higher body mass index, plasma haemoglobin and high-density lipoprotein cholesterol were also associated with carotid atherosclerosis, while other laboratory parameters considered in this study (total cholesterol, low-density lipo-

protein cholesterol, triglycerides and C-reactive protein) were not significantly associated with carotid atherosclerosis. **Conclusions:** Low plasma concentrations of antioxidant vitamins (A, E, β -carotene) and lycopene were associated with early carotid atherosclerotic lesions as measured by CIMT. Regular intake of foods rich in lycopene and antioxidant vitamins may slow the progression of atherosclerosis.

Copyright © 2008 S. Karger AG, Basel

Introduction

Cardiovascular diseases, specifically coronary heart disease and cerebrovascular diseases, are the most common causes of morbidity and mortality worldwide [1]. Moreover, cerebrovascular disease is the most important cause of long-term disability in Western societies. Oxidative stress, particularly from the oxidation of low-density lipoprotein cholesterol in the artery wall, induces an inflammatory reaction [2] which stimulates recruitment of monocytes and their differentiation into macrophages. Macrophages accumulate lipids intracellularly, forming foam cells, which results in increased thickness of the arterial wall [3–5]. Antioxidants, which may inhibit lipid peroxidation, could play an important protective role [6, 7] against the formation of simple and complex athero-

sclerotic lesions, which progressively protrude into the arterial lumen, causing stenosis or occlusion [4, 8]. In particular, increased carotid intima-media thickness (CIMT) represents an early phase of the atherosclerotic process [9–11] and is widely used as a marker of subclinical atherosclerosis which correlates with established coronary heart disease [12, 13].

Few studies have examined the relationship between plasma antioxidant concentrations and CIMT, and those that have report conflicting results. The aim of this study was to assess the relationship between asymptomatic elevated CIMT and plasma levels of antioxidants (vitamin A, vitamin E, β -carotene and lycopene).

Patients and Methods

Subjects

We enrolled 220 consecutive, asymptomatic participants (109 males, 111 females) who presented to our institute (Cardiology Unit of 'San Camillo de Lellis' Hospital, Manfredonia, Italy) between July and December 2007. The participants ranged in age from 45 to 65 years and underwent carotid ultrasound investigation of the extracranial carotid arteries.

Inclusion and Exclusion Criteria and Definitions of Clinical Parameters

Participants were identified as asymptomatic if they had not experienced a transient ischaemic attack, amaurosis fugax or stroke. Participants were excluded if they had symptomatic carotid artery disease that necessitated revascularization therapy, current infectious or inflammatory disease, recent operations or endovascular interventions, bilateral carotid occlusion, monolateral/bilateral stent implantation or monolateral/bilateral endarterectomy.

Participants were classified as current smokers if they answered 'yes' to the question 'have you smoked cigarettes, cigars, or a pipe within the past 30 days?'. Body weight was measured using a balance scale. During the height and weight measurements, the subjects wore light clothing and no shoes. Body mass index was computed as the ratio of weight in kilograms to the square of height in meters. Arterial hypertension was diagnosed in subjects with blood pressure values $>140/90$ mm Hg measured repeatedly (at least twice) and was assumed to be present in patients taking antihypertensive drugs [14]. Diabetes mellitus was defined according to the clinical practice recommendations 2002 criteria of the Expert Committee of the American Diabetes Association [15]. Hyperlipidaemia was defined as an elevation of low-density lipoprotein cholesterol values above 130 mg/dl and was assumed to be present in all patients taking lipid-lowering therapies [16].

The diagnosis of peripheral artery disease was performed according to the American College of Cardiology/American Heart Association practice guidelines [17]. Stroke was defined as a neurological deficit evaluated after 24 h by a neurologist or internist according to the American Heart Association/American Stroke Association Council guidelines [18]. History of myocardial in-

farction was assessed according to the consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction [19].

The study was performed in accordance with the Helsinki Declaration of 1975, as revised in 1983, and approved by the ethical committee of San Camillo de Lellis Hospital. All patients had to provide written informed consent.

Carotid Ultrasound Investigation

Carotid ultrasound investigations were performed by means of a colour-coded Acuson Sequoia C512 (Siemens Medical Solutions USA Inc.) carotid duplex machine with a 7.5-MHz linear transducer. The investigation included longitudinal and transverse examinations of the carotid arteries. Diameters of both the left and right carotid arteries were measured and calculated at the site of maximal stenosis in the extra-cranial common carotid arteries according to the European Carotid Surgery Trial method [20]. The CIMT measurements were performed 10 mm proximal to the carotid bulb or 20 mm proximal to the flow divider. CIMT was measured between the leading edge of the first echogenic line (lumen-intima interface) and the second echogenic line (upper layer of the adventitia) in the far (deeper) artery wall. All measurements were performed on frozen, enlarged images ($\times 2$) at the end of a heart cycle (end diastole), with the transducer in the medio-lateral direction [21]. Measurements were performed in both common carotid arteries, and the larger of the two values was used in data analysis. Offline analysis of the CIMT was performed using video images based on the Atherosclerosis Risk in Communities study protocol [22]. Carotid atherosclerosis was defined as a CIMT between 0.8 and 1.2 mm, while carotid plaque was defined as focal echo structures encroaching into the vessel lumen where the CIMT was >1.2 mm. These cut-offs were chosen because they were used in previous randomized clinical trials [23, 24].

Clinical and Laboratory Data

After carotid ultrasound investigation, medical history (hypertension, diabetes mellitus, family history of atherosclerosis, myocardial infarction, hyperlipidaemia, angina pectoris, peripheral artery disease, history of prior cerebral accident) and data from a physical examination [age, gender, body mass index, blood pressure, cardiac rate, smoking habits (smoker, ex-smoker or non-smoker)] were collected.

Venous blood samples were obtained at the baseline visit. Blood analyses included haemoglobin, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides and C-reactive protein (measured at the Analysis Laboratory of San Camillo de Lellis Hospital) and plasma concentrations of vitamin A, vitamin E, lycopene and β -carotene (measured at the Clinical Biochemistry Laboratory, Chieti, Italy). All investigators and laboratory personnel were blinded to the subjects' status. Antecubital venous blood samples from all subjects were handled identically and blindly through all stages of the blood collection, storage, retrieval and analytic processes.

Blood Sample Collection, Storage and Preparation

Blood samples were collected in polypropylene tubes containing EDTA 1 mM. Samples were stored in an ice box prior to centrifugation at 3,000 g for 10 min at 4°C. Then, 200- μ l aliquots of

Table 1. Characteristics of the study population

	CIMT <0.8 mm (n = 95)	CIMT ≥0.8 mm (n = 125)	p value
<i>Demographic data</i>			
Age, years	45.2 ± 18.3	47.5 ± 17.2	0.34
Males/females	52/43	57/68	0.48
Body mass index	25.15 ± 3.22	26.12 ± 2.87	0.02
Blood pressure, mm Hg			
Systolic	124 ± 7	130 ± 4	<0.0001
Diastolic	84 ± 6	83 ± 5	0.18
Resting pulse, beats/min	64 ± 15	66 ± 13	0.29
Smoking status			
Current smokers	45 (47.36)	64 (51.2)	0.69
Ex-smokers	12 (12.63)	16 (12.8)	0.99
Non-smokers	38 (40)	45 (36)	0.64
<i>Laboratory data</i>			
Haemoglobin, g/dl	12.65 ± 0.81	12.88 ± 0.63	0.02
Total cholesterol, mg/dl	184.46 ± 14.90	191.00 ± 35.25	0.09
HDL-C, mg/dl	48.18 ± 4.64	49.62 ± 4.56	0.02
LDL-C, mg/dl	121.72 ± 10.39	124.25 ± 34.20	0.49
Triglycerides, mg/dl	127.20 ± 24.22	130.62 ± 35.27	0.42
CRP, mg/dl	4.29 ± 2.15	3.86 ± 2.23	0.15
<i>Antioxidants</i>			
Vitamin A, µmol/l	6.00 ± 0.73	2.71 ± 0.96	<0.0001
Vitamin E, µmol/l	86.69 ± 12.15	43.48 ± 8.49	<0.0001
Lycopene, µmol/l	0.92 ± 0.43	0.34 ± 0.19	<0.0001
β-Carotene, µmol/l	3.47 ± 0.72	0.809 ± 0.39	<0.0001

Values in parentheses represent percentages. HDL-C = High-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; CRP = C-reactive protein.

plasma were transferred into foil-wrapped polypropylene tubes. Plasma samples were either used for immediate extraction or stored in the dark at -80°C until analysis was performed. Sample preparation was performed as described by Lee et al. [25].

HPLC System and Conditions for Antioxidant Measurements

Vitamin A, vitamin E, lycopene and β-carotene concentrations were determined by HPLC. Two Waters 515 HPLC pumps (Whatman, Clifton, N.J., USA) equipped with a Waters auto-injector (model 717 plus auto-sampler) and a Waters 996 photodiode array detector were used as the HPLC system. Data acquisition and processing were performed using the chromatography software Empower-Pro (Waters). Analysis was performed by isocratic elution. The flow rate was 1.5 ml/min. The mobile phases used were as follows: (A) methanol/*n*-butanol/water (89.5/5/5.5 v/v/v) premixed and vacuum filtered through a 0.45-µm polypropylene membrane filter (Whatman) before use; (B) methanol/*n*-butanol/water (76/19.5/4.5 v/v/v) premixed and vacuum filtered before use as for A. The elution isocratic profile was 0–7 min 100% A, 7–15 min 100% B and 15–20 min 100% A for column re-equil-

ibration. Auto-injections of 20 µl were performed at 5°C. The analytical column used was a replaceable Partisphere 5 C-18 cartridge with an inner diameter of 110 × 4.7 mm and particle size of 5 µm (Whatman, Waters Corporation, Milford, Mass., USA) protected by a guard cartridge (C-18, 5 µm) system and maintained at 45°C. The photodiode array wavelength ranged from 270 to 460 nm, and the chromatograms were extracted at 340 nm for vitamin A, 288 nm for vitamin E and vitamin E-acetate (used as internal standard) and 441 nm for lycopene and β-carotene. The run time was 20 min.

Statistical Analysis

Study participants were grouped into two categories according to CIMT, i.e. <0.8 and ≥0.8 mm. For each baseline characteristic, the mean value or corresponding percentage of study participants was calculated according to the CIMT category. The statistical significance of differences was examined using Student's *t* test (continuous variables) and the χ^2 test (categorical variables).

A two-sided *p* value <0.05 was considered statistically significant. Data were analyzed using SPSS statistical software (version 15.0 for Windows, SPSS Inc., Chicago, Ill., USA).

Results

Means (± SD) or percentages of patients for various demographic characteristics and established cardiovascular disease risk factors are summarized in table 1 according to CIMT category. Of the 220 participants who took part in the study, 125 subjects (56.8%) had carotid atherosclerosis, of whom 52 (41.6%) had disease localized to the common carotid arteries, 43 (34.4%) had disease localized to the internal carotid arteries and 30 (24%) had disease localized to the external carotid arteries.

A significant association was identified between low concentrations of vitamin A (*p* < 0.01), vitamin E (*p* < 0.001), lycopene (*p* < 0.01) and β-carotene (*p* < 0.001) and evidence of carotid atherosclerosis as measured by CIMT. Marginally higher body mass index, plasma haemoglobin and high-density lipoprotein cholesterol were also associated with carotid atherosclerosis, while other laboratory parameters considered in the study (total cholesterol, low-density lipoprotein cholesterol, triglycerides and C-reactive protein) were not significantly associated with carotid atherosclerosis.

Discussion

The primary finding of our study is that low plasma levels of antioxidant vitamins and oxygenated carotenoids (vitamin A, vitamin E, β-carotene and lycopene)

are associated with carotid atherosclerosis. Other epidemiological studies have evaluated the relationship between antioxidant vitamins and evidence of subclinical atherosclerosis; however, the results have been inconclusive.

For example, in a cross-sectional study of 392 men and women (age 45–65 years), D’Odorico et al. [26] found no association between vitamin A plasma concentrations and the presence of carotid/femoral atherosclerosis. Similarly, Iannuzzi et al. [27] examined 310 women for early carotid atherosclerosis and found no association between intake or plasma concentrations of vitamin A and the presence of carotid plaques. In prospective cohort studies, Dwyer et al. [28] and McQuillan et al. [29] found no association between CIMT atherosclerosis or progression and vitamin A plasma concentrations. In a nested case-control study, Iribarren et al. [30] also failed to find an association between plasma vitamin A (retinol) concentration and CIMT. In contrast, a case-control study conducted by Polidori et al. [31] found a significant association between lower plasma vitamin A (retinol) concentrations and carotid and iliofemoral atherosclerosis.

The results of published studies regarding vitamin E and carotid atherosclerosis are also inconclusive. Iannuzzi et al. [27], Polidori et al. [31] and McQuillan et al. [29] found an inverse association between CIMT and plasma vitamin E concentration, whereas D’Odorico et al. [26], Dwyer et al. [28] and Giannetti et al. [32] found no association between vitamin E plasma concentration and the presence of carotid/femoral atherosclerosis. Even for the well-studied relationship between β -carotene and carotid atherosclerosis, the results of published studies are unclear and conflicting. Many studies have found that the consumption of β -carotene is inversely related to the risk of coronary heart disease [33, 34] and that the risk of carotid and femoral atherosclerosis decreased with increasing plasma β -carotene concentrations [26], suggesting a protective role for β -carotene in early atherogenesis.

However, several well-conducted studies have found no association between β -carotene plasma concentrations and CIMT or peripheral vascular disease [29, 30, 32]. In contrast, the results of published studies of the association between lycopene and carotid atherosclerosis are generally concordant and show a significant inverse relationship between serum concentrations of lycopene and CIMT, supporting the hypothesis that plasma lycopene may decrease the risk of atherosclerosis and play an important role in the early stage of atherogenesis [29, 32, 35].

One important limitation of this study is the cross-sectional nature of our findings. Because antioxidant values, lipid profiles, anthropometrics and questionnaires were collected concurrently with the ultrasound assessment of carotid arteries, temporality cannot be inferred from these findings. Further studies which examine this important relationship are warranted.

Conclusions

In summary, we found a strong inverse relationship between antioxidant plasma levels and the presence of carotid atherosclerosis. Atherosclerosis remains clinically mute for a long time and frequently manifests itself with an acute cardiovascular event; therefore, the possibility of detecting the disease in a subclinical phase and reducing or reversing its progression is an issue of relevance. The evaluation of CIMT in asymptomatic patients with CUS allows us to identify atherosclerotic disease in its early phases, to evaluate disease progression and to monitor the effects of interventions. In particular, regular intake of rich foods rich in lycopene and other antioxidant vitamins may slow the progression of atherosclerotic processes and modify the early stages of atherosclerosis, with a consequent reduction in cardiovascular events.

References

- 1 Ezzati M, Vander Hoorn S, Lawes CM, Leach R, James WP, Lopez AD, Rodgers A, Murray CJ: Rethinking the ‘diseases of affluence’ paradigm: global patterns of nutritional risks in relation to economic development. *PLoS Med* 2005;2:e133.
- 2 Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R, Collen D, Muls E, Van de Werf F: Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. *Arterioscl Thromb Vasc Biol* 2001;21:844–848.
- 3 Libby P, Algra A, Aikawa M, Schonbeck U: Cholesterol and atherosclerosis. *Biochim Biophys Acta* 2000;1529:299–309.
- 4 Lusis AJ: Atherosclerosis. *Nature* 2000;407:233–241.
- 5 Riccioni G, De Santis A, Cerasa V, Menna V, Di Ilio C, Ballone E, D’Orazio N: Atherosclerotic plaque formation and risk factors. *Int J Immunopathol Pharmacol* 2003;16:25–31.
- 6 Diaz MN, Frei B, Vita JA, Keaney FR Jr: Antioxidants and atherosclerotic heart disease. *N Engl J Med* 1997;337:408–416.

- 7 Riccioni G, Bucciarelli T, Mancini B, Di Ilio C, Capra V, D'Orazio N: The role of the antioxidant vitamin supplementation in the prevention of cardiovascular diseases. *Expert Opin Investig Drugs* 2007;16:25–32.
- 8 Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. *N Engl J Med* 1989;320:915–924.
- 9 Zureik M, Ducimetiere P, Touboul PJ, Courbon D, Bonithon-Kopp C, Berr C, Magne C: Common carotid intima-media thickness predicts occurrence of carotid atherosclerotic plaques: longitudinal results from the Aging Vascular Study (EVA) study. *Arterioscler Thromb Vasc Biol* 2000;20:1622–1629.
- 10 Heiss G, Sharrett AR, Barnes R, Chambless LE, Szklo M, Alzola C: Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC Study. *Am J Epidemiol* 1991;134:250–256.
- 11 Salonen R, Salonen JT: Determinants of carotid intima-media thickness: a population-based ultrasonography study in eastern Finnish men. *J Intern Med* 1991;229:225–231.
- 12 Davis PH, Dawson JD, Riley WA, Lauer MN: Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: the Muscatine study. *Circulation* 2001;104:2815–2819.
- 13 Salonen JT, Salonen R: Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. *Arterioscler Thromb* 1991;11:1245–1249.
- 14 Joint National Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA* 2003;289:2560–2572.
- 15 Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: American Diabetes Association: clinical practice recommendations 2002. *Diabetes Care* 2002;25(suppl 1):S1–S147.
- 16 National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation* 2002;106:3143–3421.
- 17 ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. *Circulation* 2006;113:e463–e654.
- 18 Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. *Stroke* 2006;37:1583–1633.
- 19 Alpert JS, Thygesen K, Antman E, Bassand GP: Myocardial infarction redefined – a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. *J Am Coll Cardiol* 2000;39:959–969.
- 20 European Carotid Surgery Trialists' Collaborative Group: MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70–99%) stenosis or with mild (0–29%) stenosis. *Lancet* 1991;337:1235–1243.
- 21 Kanters SD, Algra A, van Leeuwen MS, Banga JD: Reproducibility of in vivo carotid intima-media thickness measurements. *Stroke* 1997;28:665–671.
- 22 Howard G, Sharrett AR, Heiss G, Evans GW, Chambless LE, Riley WA, Burke GL: Carotid artery intimal-medial thickness distribution in general populations as evaluated by B-mode ultrasound. *Stroke* 1993;24:1297–1304.
- 23 Crouse JR III, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, McGovern ME, Furberg CD: Pravastatin, lipids and atherosclerosis in the carotid arteries (PLAC-II). *Am J Cardiol* 1995;75:455–459.
- 24 Mercuri M, Bond MG, Sirtori CR, Veglia F, Crepaldi G, Feruglio FS, Descovich G, Ricci G, Rubba P, Mancini M, Gallus G, Bianchi G, D'Alò G, Ventura A: Pravastatin reduces intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. *Am J Med* 1996;101:627–634.
- 25 Lee BL, Chua SC, Ong HY, Ong CN: High-performance liquid chromatographic method for routine determination of vitamins A and E and β -carotene. *J Chromatogr* 1999;581:41–47.
- 26 D'Odorico A, Martinez D, Kiechl S, Egger G, Ozer F, Bonvicini P, Sturinolo GC, Naccarato R, Willeit J: High plasma levels of alpha- and beta-carotene are associated with a lower risk of atherosclerosis. Results from the Bruneck study. *Atherosclerosis* 2000;153:231–239.
- 27 Iannuzzi A, Celentano E, Panico S, Galasso R, Covetti G, Sacchetti L, Zarrilli F, De Michele M, Rubba P: Dietary and circulating antioxidant vitamins in relation to carotid plaques in middle-aged women. *Am J Clin Nutr* 2002;3:582–587.
- 28 Dwyer JH, Paul-Labrador MJ, Fan J, Shircore AM, Bairez Merz CN, Dwyer KM: Progression of carotid intima-media thickness and plasma antioxidants: the Los Angeles Atherosclerosis Study. *Arterioscler Thromb Vasc Biol* 2004;24:313–318.
- 29 McQuillan BM, Hung J, Beilby JP, Nidorf M, Thompson PL: Antioxidant vitamins and the risk of carotid atherosclerosis. The Perth Carotid Ultrasound Assessment study (CUDAS). *J Am Coll Cardiol* 2001;38:1788–1794.
- 30 Iribarren C, Folsom AR, Jacobs DR Jr, Gross MD, Belcher JD, Eckfeldt JH: Association of serum vitamin levels, LDL susceptibility to oxidation, and autoantibodies against MDA-LDL with carotid atherosclerosis. A case-control study. The ARIC Study Investigators. *Arterioscler Thromb Vasc Biol* 1997;7:1171–1177.
- 31 Polidori MC, Praticò D, Parente B, Mariani E, Cecchetti R, Yao Y, Sies H, Cao P, Mecocci P, Sthal W: Elevated lipid peroxidation biomarkers and low antioxidant status in atherosclerosis patients with increased carotid or iliofemoral intima media thickness. *J Invest Med* 2007;55:163–167.
- 32 Giannetti J, Perinelli R, Petrucci R, Lazzerini G, De caterina M, Bellomo G, De Caterina R: Inverse association between carotid intima-media thickness and the antioxidant lycopene in atherosclerosis. *Am Heart J* 2002;143:467–474.
- 33 Bolton-Smith C, Woodward M, Tunstall-Pedoe H: The Scottish Heart Health Study. Dietary intake by food frequency questionnaire and odds ratios for coronary heart disease risk. II. The antioxidant vitamins and fibre. *Eur J Clin Nutr* 1992;46:85–93.
- 34 Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC: Vitamin E consumption and the risk of coronary heart disease in men. *N Engl J Med* 1993;328:1450–1456.
- 35 Rissanen TH, Voutilainen S, Nyyssönen K, Salonen R, Kaplan GA, Salonen JT: Serum lycopene concentrations and carotid atherosclerosis: the Kuopio Ischaemic Heart Disease Risk Factor Study. *Am J Clin Nutr* 2003;77:13–18.